The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Outcomes from a study on immune reconstitution after non-myeloablative alloSCT in MF
Morten Orebo Holmström, MD, PhD, National Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen, Denmark, discusses findings from a study on immune reconstitution after allogeneic stem cell transplantation (alloSCT) in myelofibrosis (MF). He highlights an unexpected result: the number of donor-derived T-cells had an impact on non-relapse mortality. Dr Holmström emphasizes that T-cell quantity alone is insufficient for predicting patient outcomes, and future strategies should focus on performing functional immune analyses to better understand post-transplant outcomes. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
